J. R. Verner C. W. Weiant R. J. Watkins
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Gene, Vaccine and Immuno- Therapies Against Cancer: New Approaches to an Old Problem
EUROPEAN PARLIAMENT Scientific Technology Options Assessment S T O A Gene, Vaccine and Immuno- therapies against Cancer: New Approaches to an Old Problem Results of the project “Future Development of Cancer Therapy” Study (IP/A/STOA/FWC/2005-28/SC17) IPOL/A/STOA/ST/2006-21 PE 383.215 P This publication is the result of a project commissioned by STOA under Framework Contract IP/A/STOA/FWC/2005-28 on "Future Development of Cancer Therapy". It contains contributions and discussions arising from a workshop that took place at the European Parliament in Brussels in February 2007 under the title "Gene, Vaccine and Immuno- therapies against Cancer: New Approaches to an Old Problem". Only published in English. Authors: ETAG European Technology Assessment Group Institute for Technology Assessment and Systems Analysis (ITAS), Karlsruhe Danish Board of Technology (DBT), Copenhagen Flemish Institute for Science and Technology Assessment (viWTA), Brussels Parliamentary Office of Science and Technology (POST), London Rathenau Institute, The Hague Volker Reuck, ITAS E-mail: [email protected] Arnold Sauter, ITAS E-mail: [email protected] Administrator: Mr Marcelo Sosa-Iudicissa Policy Department A: Economic and Scientific Policy DG Internal Policies European Parliament Rue Wiertz 60 - ATR 00K066 B-1047 Brussels Tel: +32 (0)2 284 17 76 Fax: +32(0)2 284 69 29 E-mail: [email protected] Manuscript completed in February 2007. The opinions expressed in this document do not necessarily represent the official position of the European Parliament. Reproduction and translation for non-commercial purposes are authorised provided the source is acknowledged and the publisher is given prior notice and receives a copy. -
Therapeutic Vaccines for Cancer: an Overview of Clinical Trials
REVIEWS Therapeutic vaccines for cancer: an overview of clinical trials Ignacio Melero, Gustav Gaudernack, Winald Gerritsen, Christoph Huber, Giorgio Parmiani, Suzy Scholl, Nicholas Thatcher, John Wagstaff, Christoph Zielinski, Ian Faulkner and Håkan Mellstedt Abstract | The therapeutic potential of host-specific and tumour-specific immune responses is well recognized and, after many years, active immunotherapies directed at inducing or augmenting these responses are entering clinical practice. Antitumour immunization is a complex, multi-component task, and the optimal combinations of antigens, adjuvants, delivery vehicles and routes of administration are not yet identified. Active immunotherapy must also address the immunosuppressive and tolerogenic mechanisms deployed by tumours. This Review provides an overview of new results from clinical studies of therapeutic cancer vaccines directed against tumour-associated antigens and discusses their implications for the use of active immunotherapy. Melero, I. et al. Nat. Rev. Clin. Oncol. 11, 509–524 (2014); published online 8 July 2014; doi:10.1038/nrclinonc.2014.111 Centro de Investigación Medica Aplicada (CIMA) Introduction and Clínica Universitaria (CUN), Universidad de Immunotherapies against existing cancers include active, unstable leading to numerous changes in the repertoire Navarra, Spain (I.M.). passive or immunomodulatory strategies. Whereas active of epitopes (so-called neo-antigens) they present, sug- Department of Immunology, immunotherapies increase the ability of the patient’s gesting that, in theory, tumours should be ‘visible’ to The Norwegian Radium own immune system to mount an immune response T lymphocytes. Hospital, Cancer to recognize tumour-associated antigens and eliminate The mechanisms required to mount effective anti Research Institute, University of Oslo, malignant cells, passive immunotherapy involves admin- tumour responses have been reviewed by Mellman and Norway (G.G.). -
Cholera Cholera
WORLD HEALTH ORGASIZATION MONOGRAPH SERIES No. 43 CHOLERA CHOLERA R. POLLITZER, M.D. George Williams Hooper Foundation, University of California, San Francisco, USA (Formerly of the Division of Communicable Disease Services, World Health Organization) With a Chapter on World Incidence written in collaboration with S. SWAROOP, Ph. D. M.P.H. Chief, Statistical Studies Section, World Health Organization And a Chapter on Problems in Immunology and an Annex written in collaboration with W. BURROWS, ~1. D. Professor of 1'vficrobiology, Unilwsity of Chicago, Chicago, I11., [iSA WORLD HEALTH ORGANIZATION PALAIS DES NATIONS GENEVA 1959 Authors alone are responsible for the yiews expressed in the Monograph Series of the World Health Organization. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in prefer ence to others of a similar nature which are not mentioned. Proprietary names are distinguished by initial capital letters. PRINTED IN SWITZERLAND CONTENTS Page Preface . 7 Acknowledgements 9 Chapter 1. History of the disease 11 Chapter 2. World incidence, written in collaboration with S. Swaroop 51 Chapter 3. Bacteriology . 97 Chapter 4. Problems in immunology, written in collabor- ation with W. Burrows 202 Chapter 5. Bacteriophage investigations . 373 Chapter 6. General pathology and morbid anatomy 397 Chapter 7. Practical laboratory diagnosis 523 Chapter 8. Clinical pathology 607 Chapter 9. Symptomatology, diagnosis, prognosis and treatment 684 Chapter 10. Epidemiology 820 Chapter 11. Prevention and control 893 Annex. Examination of cholera-suspect stool specimens, written in collaboration with W. Burrows 991 Index . 1001 -5- Preface It would be no exaggeration to say that it was through cholera, and the fear to which its pandemic sweeps gave rise, that international solidarity in matters of health was born. -
The Greatest Steps Towards the Discovery of Vibrio Cholerae
REVIEW 10.1111/1469-0691.12390 The greatest steps towards the discovery of Vibrio cholerae D. Lippi1 and E. Gotuzzo2 1) Experimental and Clinical Medicine, University of Florence, Florence, Italy and 2) Institute of Tropical Medicine, Peruvian University, C. Heredia, Lima, Peru Abstract In the 19th century, there was extensive research on cholera: the disease was generally attributed to miasmatic causes, but this concept was replaced, between about 1850 and 1910, by the scientifically founded germ theory of disease. In 1883, Robert Koch identified the vibrion for the second time, after Filippo Pacini’s discovery in 1854: Koch isolated the comma bacillus in pure culture and explained its mode of transmission, solving an enigma that had lasted for centuries. The aim of this article is to reconstruct the different steps towards the explanation of cholera, paying particular attention to the events occurring in the pivotal year 1854. Keywords: Filippo Pacini, history of cholera, John Snow, Robert Koch, vibrion Clin Microbiol Infect Corresponding author: D. Lippi, Experimental and Clinical Medicine, University of Florence, Florence, Italy E-mail: donatella.lippi@unifi.it seriously affected almost the whole world during many severe Introduction outbreaks in the course of the 19th century [2]. This diarrhoeal disease can lead to death by dehydration of an untreated In the 19th century, there was extensive research on cholera: patient within a few hours, and is extremely contagious in among the topics discussed were microbial vs. miasmatic causes communities without adequate sanitation. Even though it was and the relative merits of hygiene, sanitation and quarantine in hard to discriminate cholera from many other diseases controlling or preventing cholera’s spread, especially among associated with diarrhoea and vomiting, the first pandemic of European nations. -
WHO-MONO-43-Part2-Eng.Pdf (7.791MB)
356 CHOLERA Gallut, J. (1953c) Relations antigeniques entre vibrion cholerique .et brucelles. 11. Sur la fraction antigenique thermostable commune. Ann. Inst. Pasteur, 85, 261 Gallut, J. (1953d) Variation du pouvoir toxique de Vibrio cholerae au cours de la mala die. C. R. Acad. Sci. (Paris), 237, 1038 Gallut, J. (1954a) Contribution a !'etude de la toxine cholerique. Variation du pouvoir toxique de Vibrio clwlerae (Ogawa) au cours de la maladie. Ann. Inst. Pasteur, 86, 561 Gallut, J. (l954b) La seroagglutination dans le diagnostic retrospectif du cholera. Expose critique. Bull. Soc. Path. exot. 47, 657 Gallut, J. (1955) Contribution a !'etude de la toxine cholerique. Influence de la tempe rature d'incubation sur le pouvoir toxigene in vitro de Vibrio cholerae. Ann. Inst. Pasteur, 89, 242 Gallut, J. & Brounst, G. (1949) Sur la mise en evidence des agglutinines choleriques. Ann. Inst. Pasteur, 76, 557 Gallut, J. & Brumpt, L. C. (1944) Application experimentale de l'hemoagglutination rapide du vibrion cholerique. Ann. Inst. Pasteur, 70, 62 Gallut, J. & Grabar, P. (l943a) Recherches immunochimiques sur le vibrion cholerique. I. Etude quantitative de la reaction de precipitation de l'antigime glucidolipidique par l'immunserum de lapin. Ann. Inst. Pasteur, 69, 250 Gallut, J. & Grabar, P. (l943b) Recherches immunochimiques sur le vibrion cholerique. II. Sur les constituants de la toxine cholerique. Ann. Inst. Pasteur, 69, 307 Gallut, J. & Grabar, P. (1945) Recherches immunochimiques sur le vibrion cholerique. Ill. Mise en evidence de deux constituants toxiques de nature differente dans la toxine cholerique. Ann. Inst. Pasteur, 71, 83 Gallut, J. & Grabar, P. (1947) Recherches immunochimiques sur le vibrion cholerique. -
Final Program
FINAL PROGRAM SOCIETY FOR IMMUNOTHERAPY OF CANCER 26 TH ANNUAL MEETING NOVEMBER 4-6, 2011 • NORTH BETHESDA, MD www.sitcancer.org SITC Supporters (As of September 27, 2011) GENERAL EDUCATION SUPPORTERS SILVER BRONZE Center for Cancer Research National Cancer Institute National Institutes of Health Health and Human Services COPPER ANNUAL MEETING SUPPORTERS PLATINUM GOLD SILVER BRONZE (Annual Meeting Abstract Book) COPPER (2 Young Investigator Awards) FINAL PROGRAM • SITC 26 TH ANNUAL MEETING November 4-6, 2011 • North Bethesda, MD • www.sitcancer.org Table of Contents GENERAL INFORMATION Message from the President . ........................2 INFORMATION Meeting at a Glance . ..............................3 GENERAL General Meeting Information . ..........................4 Hotel Information. ..................................7 Hotel Map . ......................................8 ASSOCIATED PROGRAM DETAILS Associated Programs . .............................9 26 TH ANNUAL MEETING DETAILS Early Career Scientists Committee Information . ..........11 Presidential and Travel Awards . ............................12 Richard V. Smalley, MD, Memorial Award and Lectureship. ..........14 Plenary and Concurrent Sessions. ....................15 Program Schedule . ...............................17 Faculty Listing . ...................................24 Disclosures . ....................................26 EXHIBIT INFORMATION Exhibit and Poster Hall Floor Plan . ..................29 Exhibitor Listing . ................................30 ABOUT SITC SITC Membership -
Cancer Vaccines: Promising Therapeutics Or an Unattainable Dream
Review Cancer Vaccines: Promising Therapeutics or an Unattainable Dream Howard Donninger 1,2,†, Chi Li 1,3,†, John W. Eaton 2,4 and Kavitha Yaddanapudi 4,5,6,* 1 James Graham Brown Cancer Center, Experimental Therapeutics Group, University of Louisville, Louisville, KY 40202, USA; [email protected] (H.D.); [email protected] (C.L.) 2 Department of Medicine, University of Louisville, Louisville, KY 40202, USA; [email protected] 3 Department of Pharmacology & Toxicology, University of Louisville, Louisville, KY 40202, USA 4 James Graham Brown Cancer Center, Immuno-Oncology Group, University of Louisville, Louisville, KY 40202, USA 5 Department of Surgery, Division of Immunotherapy, University of Louisville, Louisville, KY 40202, USA 6 Department of Microbiology/Immunology, University of Louisville, Louisville, KY 40202, USA * Correspondence: [email protected] † Contributed equally. Abstract: The advent of cancer immunotherapy has revolutionized the field of cancer treatment and offers cancer patients new hope. Although this therapy has proved highly successful for some patients, its efficacy is not all encompassing and several cancer types do not respond. Cancer vaccines offer an alternate approach to promote anti-tumor immunity that differ in their mode of action from antibody-based therapies. Cancer vaccines serve to balance the equilibrium of the crosstalk between the tumor cells and the host immune system. Recent advances in understanding the nature of tumor-mediated tolerogenicity and antigen presentation has aided in the identification of tumor antigens that have the potential to enhance anti-tumor immunity. Cancer vaccines can either be Citation: Donninger, H.; Li, C.; prophylactic (preventative) or therapeutic (curative). An exciting option for therapeutic vaccines Eaton, J.W.; Yaddanapudi, K. -
9260 DETECTION of PATHOGENIC BACTERIA* 9260 A. Introduction
9260 DETECTION OF PATHOGENIC BACTERIA* 9260 A. Introduction 1. General Discussion cludes 11 microbes for methods development and potential fu- ture regulation.8,9 One purpose of drinking water and wastewater treatment is to Water contamination and disease transmission may result reduce the numbers of viable organisms to acceptable levels, and from conditions generated at overloaded and/or malfunctioning to remove or inactivate all pathogens capable of causing human sanitary waste disposal and potable water treatment systems. In disease. Despite the remarkable success of water treatment and addition, common outdoor recreational activities, such as swim- sanitation programs in improving public health, sporadic cases ming (including pools and hot tubs), wind surfing, and water- and point-source outbreaks of waterborne diseases continue to skiing, all place humans at risk of waterborne diseases from occur. Water and wastewater may contain a wide variety of ingestion or direct contact with contaminated water.10 Outbreaks bacteria that cause intestinal or extra-intestinal infections. Wa- of gastroenteritis, pharyngoconjunctivitis, folliculitis, otitis, and terborne pathogens enter human hosts through intact or compro- pneumonia are associated with these recreational activities. mised skin, inhalation, ingestion, aspiration, and direct contact Overcrowded parks and recreational areas contribute to the con- with the mucous membranes of the eye, ear, nose, mouth, and tamination of surface and groundwater. genitals. This section provides an introduction to bacterial agents Laboratory diagnosis of infectious disease depends on detec- responsible for diseases transmitted by drinking and recreational tion or isolation of the etiologic agent or demonstration of waters in the United States. antibody response in the patient. -
Efficacy of Experimental Phage Therapies in Livestock
Animal Health Research Efficacy of experimental phage therapies Reviews in livestock cambridge.org/ahr Marta Dec , Andrzej Wernicki and Renata Urban-Chmiel Sub-Department of Veterinary Prevention and Avian Diseases, Institute of Biological Basis of Animal Diseases, Faculty of Veterinary Medicine, University of Life Sciences, Akademicka 12, 20-033 Lublin, Poland Review Cite this article: Dec M, Wernicki A, Abstract Urban-Chmiel R (2020). Efficacy of Bacteriophages are the most abundant form of life on earth and are present everywhere. The total experimental phage therapies in livestock. number of bacteriophages has been estimated to be 1032 virions. The main division of bacterio- Animal Health Research Reviews 21,69–83. https://doi.org/10.1017/S1466252319000161 phages is based on the type of nucleic acid (DNA or RNA) and on the structure of the capsid. Due to the significant increase in the number of multi-drug-resistant bacteria, bacteriophages Received: 6 August 2019 could be a useful tool as an alternative to antibiotics in experimental therapies to prevent and Revised: 18 November 2019 to control bacterial infections in people and animals. The aim of this review was to discuss Accepted: 19 November 2019 the history of phage therapy as a replacement for antibiotics, in response to EU regulations First published online: 19 June 2020 prohibiting the use of antibiotics in livestock, and to present current examples and results of Key words: experimental phage treatments in comparison to antibiotics. The use of bacteriophages to control Bacteriophages; experimental therapies; human infections has had a high success rate, especially in mixed infections caused mainly by livestock; pathogens Staphylococcus, Pseudomonas, Enterobacter,andEnterococcus. -
A Historical Overview of the Therapeutic Use of Bacteriophages
A historical overview of the therapeutic use of bacteriophages Andrzej Górski ¹ ², Beata Weber-Dąbrowska ¹, Ryszard Międzybrodzki ¹ ², Jan Borysowski ² ¹ Bacteriophage Laboratory & Therapy Center, L.Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wrocław, Poland ² Department of Clinical Immunology, T.Orlowski Transplantation Institute, The Medical University of Warsaw, 02-006 Warsaw, Poland The milestones in phage history Elbreki et al., 2014, Journal of Viruses ,vol.2014, Article ID 382539 Hankin published his observations in 1896 in the annals of the Institut Pasteur – that was the first evidence of the presence of bacteriophages in water and their antibacterial activities. It was a viral-like agent with antibacterial properties. It was temperature sensitive and capable of passing through a porcelain filter, and it could reduce titres of the bacterium Vibrio cholerae in laboratory cultures. "L'action bactericide des eaux de la Jumna et du Gange sur le vibrion du cholera„ Annales de l'Institut Pasteur (in French) 1896; 10: 511–523. In 1915 The Lancet published an article written by Frederick Twort about ‘‘the transmissible bacterial lyses’’. It was the first publication on bacteriophages. The Lancet, Jan. 10th, 1914, p. 101 Courtesy of Ms Grace Philby Courtesy of Ms Grace Philby Felix d'Herelle In 1917 Félix d’Herelle isolated first bacteriophages from the stools of patients recovering from dysentery*. He supposed that bacteriophages were agents that cause natural recoveries*. He showed that bacteriophages could be used to treat bacterial infections in humans*. Felix d'Herelle at a bacteriophage Bacteriophages have been used in research center. medicine since 1919, ten years .Thacker PD. -
Oral Presentations 2019 AANS Annual Scientific Meeting San Diego, CA • April 13–17, 2019
AANS 2019 Annual Scientific Meeting Abstracts Oral Presentations 2019 AANS Annual Scientific Meeting San Diego, CA • April 13–17, 2019 (DOI: 10.3171/2019.7.JNS.AANS2019abstracts) Disclaimer: The Journal of Neurosurgery Publishing Group (JNSPG) acknowledges that the preceding abstracts are published as submitted and did not go through JNSPG’s peer-review or editing process. 100. A Multidisciplinary Approach to Improve Communication Between Pediatric Neurosurgery and Pediatric Nurses: A Team Communication Tool Pilot Elisha Peregino, RN, MS, CRNP PNP-AC, HTPA (Hershey, PA) Introduction: Surgical services that work in open admission units often encompass various difficulties with managing their patients related to daily work flow in comparison with traditional medical services. A Neurosurgery Nursing Communication Tool (NNCT) was adapted to the pediatric neurosurgery (NSGY) population to improve team communication and understanding of patient care. There is limited research on rounding tools amongst the multi-disciplinary care team especially NSGY with nurses (RNs). Methods: This is a prospective cohort study utilizing a pre/post-implementation surveys with RNs on the pediatric unit was distributed to assess perceptions of baseline team communication. Each NNCT was assessed for various data components. Results: The pre-implementation survey showed that 63% felt their concerns were addressed and 42% feel confident speaking in team rounds. In the first month, there was a NNCT completion rate of 65% with less than 50% of NCCT data completed. Admission diagnoses were only correct on 55.6% of NCCTs. Post implementation surveys showed 85.7% felt it was user friendly. All RNs felt it took less than 5 minutes to complete. -
Microbial Taxonomy in the Post‑Genomic Era: Rebuilding from Scratch?
Arch Microbiol DOI 10.1007/s00203-014-1071-2 OPINION PAPER Microbial taxonomy in the post‑genomic era: Rebuilding from scratch? Cristiane C. Thompson · Gilda R. Amaral · Mariana Campeão · Robert A. Edwards · Martin F. Polz · Bas E. Dutilh · David W. Ussery · Tomoo Sawabe · Jean Swings · Fabiano L. Thompson Received: 25 October 2014 / Revised: 4 December 2014 / Accepted: 5 December 2014 © Springer-Verlag Berlin Heidelberg 2014 Abstract Microbial taxonomy should provide adequate Short history of microbial taxonomy descriptions of bacterial, archaeal, and eukaryotic micro- bial diversity in ecological, clinical, and industrial environ- The history of microbial taxonomy during the last ments. Its cornerstone, the prokaryote species has been re- 100 years is one of a scientific field in which progress evaluated twice. It is time to revisit polyphasic taxonomy, and conservatism meet. It is progressive as it incorpo- its principles, and its practice, including its underlying rates the most advanced technologies, yet conservative pragmatic species concept. Ultimately, we will be able to because it adheres to standards and rules. A number of realize an old dream of our predecessor taxonomists and technological driving forces were operative during its build a genomic-based microbial taxonomy, using stand- development as a scientific discipline: the introduction ardized and automated curation of high-quality complete of metabolic and phenotypic characterization of bacteria, genome sequences as the new gold standard. numerical analysis of phenotypic data (Sneath and Sokal 1973), DNA–DNA hybridizations (DDH) and %G C + Keywords Bacteria · Archaea · Microbes · Taxonomy · determinations (De Ley 1970), 16S rRNA gene sequenc- Genomics · Evolution · Open access ing (Woese and Fox 1977), and multilocus sequence analysis (MLSA) (Gevers et al.